柳生 茂希講師

専門領域 小児腫瘍学／遺伝子細胞治療
学会認定医
  • 日本小児科学会 小児科専門医
  • 日本血液学会 血液専門医
  • がん治療認定医機構 がん治療認定医
  • 日本小児血液・がん学会　小児血液・がん専門医

経歴

  • 平成12年3月

    京都府立医科大学医学部卒業

  • 平成12年4月

    京都府立医科大学附属病院 小児科研修医

  • 平成13年4月

    大津市民病院 小児科研修医、専攻医

  • 平成15年4月

    京都市立病院 小児科

  • 平成17年4月

    京都府立医科大学大学院医学研究科博士課程入学

  • 平成21年3月

    京都府立医科大学大学院医学専攻科博士課程修了

  • 平成21年4月

    京都府立与謝の海病院 小児科／京都府立医科大学小児科学教室 助教（併任）

  • 平成23年4月

    京都府立医科大学小児科学教室 助教

  • 平成25年2月

    Postdoctoral Associate, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA

  • 平成27年8月

    京都府立医科大学小児科学教室 助教

  • 平成31年4月

    京都府立医科大学小児科学内講師　現在に至る

受賞歴

  • 　

    Merit Award, International Cancer Research Symposium of Training Plan for Oncology Professionals 2018

  • 　

    日本小児血液がん学会学術賞　2017

  • 　

    Meritorious Abstract Travel Award, 18th Annual Meeting of American Society of Gene and Cell therapy, May 2015

  • 　

    Global Grant Scholarship, The Rotary Foundation, October 2012

  • 　

    Best Poster Award, 43rd Congress of the International Society of Paediatric Oncology, October 2011

学会役員歴

  • 日本遺伝子細胞治療学会　評議員
  • 日本免疫治療学会　運営委員
  • 日本小児がん研究グループ　神経芽腫委員会委員
  • 日本小児がん研究グループ　胚細胞腫瘍委員会委員
  • 日本小児がん研究グループ　早期相試験推進委員会委員

所属学会

  • 日本小児科学会
  • 日本小児血液・がん学会
  • 日本血液学会
  • 日本遺伝子細胞治療学会
  • 日本免疫治療学会
  • American Society of Gene and Cell Therapy

研究内容

  1. がんに対する遺伝子細胞療法の開発

代表的論文

  1. Yagyu S, Nakazawa Y. piggyBac-transposon-mediated CAR-T cells for the treatment of hematological and solid malignancies. Int J Clin Oncol. https://doi.org/10.1007/s10147-023-02319-9, 2023

  2. Nakashima I, Saito S, Akahoshi E, Yagyu S, Sugano-Ishihara M, Nakazawa Y. Non-viral inducible caspase 9 mRNA delivery using lipid nanoparticles against breast cancer: An in vitro study. Biochem Biophys Res Commun. 20;635:144-153. doi: 10.1016/j.bbrc.2022.09.105. 2022

  3. Suematsu M, Yagyu S, Yoshida H, Osone S, Nakazawa Y, Sugita K, Imamura T, Iehara T. Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement. Cancer Immunol Immunother. 10. doi: 10.1007/s00262-022-03303-4. 2022

  4. Suematsu M, Yagyu S, Nagao N, Kubota S, Shimizu Y, Tanaka M, Nakazawa Y, Imamura T. PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function. Front. Immunol. 13:770132. doi: 10.3389/fimmu.2022.770132, 2022

  5. Suematsu M, Yagyu S, Hosoi H, Iehara T. Infantile mediastinal neuroblastoma presenting as an oncologic emergency: usefulness of serum-based MYCN gene amplification analysis for risk stratification. BMJ Case Rep 2021 Dec 31;14(12):e246889.

  6. Tomida A, Yagyu S, Nakamura K, Kubo H, Yamashima K, Nakazawa Y, Hosoi H, Iehara T. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma. Cancer Sci. Oct;112(10):4026-4036. 2021

  7. Yagyu S, Mochizuki H, Yamashima K, Kubo H, Saito S, Tanaka M, Sakamoto K, Shimoi A, Nakazawa Y. Lymphodepleted non-human primate model for the assessment of acute on-target and off-target toxicity of human CAR-T cells. Clin Transl Immunol 10(6):e1291, 2021

  8. Hasegawa A, Saito A, Narimatsu S, Nakano S, Nagai M, Ohnota H, Inada Y, Morokawa H, Nakashima I, Morita D, Ide Y, Matsuda K, Tashiro H, Yagyu S, Tanaka M, Nakazawa Y. Mutated GM-CSF-based CAR T-cells targeting CD116/CD131 complexes exhibit enhanced anti-tumor effects against AML. Clin Transl Immunol 10(5):e1282, 2021

  9. Nakamura K, Yagyu S, Hirota S, Tomida A, Kondo M, Shigeura T, Hasegawa A, Tanaka M, Nakazawa Y. Autologous antigen-presenting cells efficiently expand piggyBac transposon chimeric antigen receptor T cells with predominant memory phenotype. Mol Ther Methods Clin Dev 21:315-324, 2021

  10. Kubo H, Yagyu S, Nakamura K, Yamashima K, Tomida A, Kikuchi K, Iehara T, Nakazawa Y, Hosoi H. Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma. Mol Ther Oncolytics 20:646-658, 2021

  11. Morokawa H, Yagyu S, Hasegawa A, Tanaka M, Saito S, Mochizuki H, Sakamoto K, Shimoi A, Nakazawa Y. Autologous non-human primate model for safety assessment of piggyBac transposon-mediated chimeric antigen receptor T cells on granulocyte-macrophage colony-stimulating factor receptor. Clin Transl Immunol. 22;9(11):e1207, 2020

  12. Yagyu S, Iehara T, Tanaka S, Gotoh T Misawa-Furihata A, Sugimoto T, London WB, Hogarty MD, Teramukai S, Nakagawara A, Hiyama E, Maris JM, Hosoi H. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. Plos One 11(8) e0161039, 2016

  13. Yagyu S, Hoyos V, Del Bufalo F, Brenner MK. Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch. Mol Ther. Methods Clin Dev 16003, 2016

  14. Del Bufalo F, Manzo T, Hoyos V, Yagyu S, Caruana I, Jacot J, Benavides O, Rosen D, Brenner MK. 3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirus. Biomaterials. 84:76-85, 2016

  15. Hoyos V, Del Bufalo F, Yagyu S, Ando M, Dotti G, Suzuki M, Bouchier-Hayes L, Alemany R, Brenner MK. Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 23(9):1497-506, 2015

  16. Yagyu S, Hoyos V, Del Bufalo F, Brenner MK. An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. Mol Ther. 23(9):1475-85, 2015

  17. Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 125(25):3905-16, 2015

  18. Ando M, Hoyos V, Yagyu S, Tao W, Ramos CA, Dotti G, Brenner MK, Bouchier-Hayes L. Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther. 21(11):472-82. 2014

  19. Farzad L, Cerullo V, Yagyu S, Bertin T, Hemminki A, Rooney C, Lee B, Suzuki M. Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy. Mol Ther Oncolytics. 1:14008, 2014

  20. Yagyu S, Iehara T, Gotoh T, Miyachi M, Katsumi Y, Kikuchi K, Tsuchiya K,Osone S, Kuroda H, Sugimoto T, Sawada T, Hosoi H. Preoperative analysis of 11q loss using circulating tumor-released DNA in serum: a novel diagnostic tool for therapy stratification of neuroblastoma. Cancer Lett. 309(2):185-9, 2011

  21. Yagyu S, Gotoh T, Iehara T, Miyachi M, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tamura S, Tsuchiya K, Imamura T, Misawa-Furihata A, Sugimoto T, Sawada T, Hosoi H. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma. Clin Cancer Res. 14(21):7011-9, 2008

  22. Yagyu S, Morimoto A, Kakazu N, Tamura S, Fujiki A, Nakase Y, Iehara T, Hosoi H, Kuroda H. Late appearance of a Philadelphia chromosome in a patient with therapy-related acute myeloid leukemia and high expression of EVI1. Cancer Genet Cytogenet. 180(2):115-20, 2008

  23. Yagyu S, Kuroda H, Fujiki A, Tamura S, Iehara T, Morimoto A, Hosoi H, Sugimoto T, Imashuku S. Successful non-T-cell-depleted HLA-haploidentical 3-loci mismatched bone marrow transplantation. Eur J Haematol. 74(6):529-32, 2005